Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1997-8-25
|
pubmed:abstractText |
Antibodies to tumor necrosis factor (TNF)-alpha have been recently proposed as effective treatment for patients with Crohn's disease. Here, we analyze the functional role of TNF-alpha in a mouse model of chronic intestinal inflammation induced by the hapten reagent 2,4,6,-trinitrobenzene sulfonic acid (TNBS) that mimics some characteristics of Crohn's disease in humans. Macrophage-enriched lamina propria (LP) mononuclear cells from mice with TNBS-induced colitis produced 10-30-fold higher levels of TNF-alpha mRNA and protein than cells from control mice. When mice with chronic colitis were treated by intraperitoneal injection of antibodies to TNF-alpha, an improvement of both the clinical and histopathologic signs of disease was found. Isolated macrophage-enriched LP cells from anti-TNF-alpha-treated mice produced strikingly less pro-inflammatory cytokines such as interleukin (IL)-1 and IL-6 in cell culture. The predominant role of TNF-alpha in the mouse TNBS-induced colitis model was further underlined by the finding that striking colonic inflammation and lethal pancolitis was induced in TNF-alpha-transgenic mice upon TNBS treatment. Conversely, no significant TNBS-induced colitis could be induced in mice in which the TNF-alpha gene had been inactivated by homologous recombination. Complementation of TNF-alpha function in TNF-/- mice by the expression of a mouse TNF-alpha transgene was sufficient to reverse this effect. Taken together, the data provide direct evidence for a predominant role of TNF-alpha in a mouse model of chronic intestinal inflammation and encourage further clinical trials with antibodies to TNF-alpha for the treatment of patients with Crohn's disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0014-2980
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1743-50
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9247586-Animals,
pubmed-meshheading:9247586-Antibodies,
pubmed-meshheading:9247586-Chronic Disease,
pubmed-meshheading:9247586-Colitis,
pubmed-meshheading:9247586-Disease Models, Animal,
pubmed-meshheading:9247586-Female,
pubmed-meshheading:9247586-Inflammatory Bowel Diseases,
pubmed-meshheading:9247586-Mice,
pubmed-meshheading:9247586-Mice, Inbred Strains,
pubmed-meshheading:9247586-Mice, Knockout,
pubmed-meshheading:9247586-Mice, Transgenic,
pubmed-meshheading:9247586-Trinitrobenzenesulfonic Acid,
pubmed-meshheading:9247586-Tumor Necrosis Factor-alpha
|
pubmed:year |
1997
|
pubmed:articleTitle |
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.
|
pubmed:affiliation |
Laboratory of Immunology, I. Medical Clinic, University of Mainz, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|